Results from a recent phase 2 clinical trial of ilixadencel plus sunitinib for the treatment of  newly-diagnosed metastatic renal cell carcinoma (RCC) were presented at the 2020 American Society of Clinical Oncology (ASCO)/Society for Immunotherapy of cancer (SITC) Clinical Immuno-Oncology Symposium, in Orlando, Florida, in February.

Ilixadencel is an immune primer designed to increase the body’s defence against cancer cells. It uses immune cells called dendritic cells, which play a key role in the activation of T-cells, immune cells that destroy cancer cells. The study discovered that addition of ilixadencel to standard surgical and medical treatment for newly-diagnosed metastatic RCC increases patient responses, duration of response, and appears to help people live longer. However, more time and study is needed to confirm the survival data, researchers say.

Read more on Immuno-Oncology News here